Currax Secures Reliable and Consistent Supply of CONTRAVE®/MYSIMBA with FDA Approval for Second Manufacturing Site
Hand-out
Press Releases
March 20, 2025

Currax Secures Reliable and Consistent Supply of CONTRAVE®/MYSIMBA with FDA Approval for Second Manufacturing Site

BRENTWOOD, Tenn., March 20, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty pharmaceutical company and manufacturer of the #1 branded oral weight loss medication CONTRAVE® (naltrexone HCl/bupropion HCl today

bradford

The Bradford Era

Local & Social